Previous studies have demonstrated that CKD-602, a TOP1 inhibitor, is effective in the treatment of various cancers such as small cell lung carcinoma, oral squamous cell carcinoma and glioblastoma (Kim et al., 2013; Kim et al., 2015; Lee et al., 1998). Here, TOP1 is linked to oral cavity squamous cell carcinoma.